Healthcare Services

Hepatorenal Syndrome Market: Trends, Drivers, and Opportunities

April 22, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Hepatorenal Syndrome Market Projected To Reach By 2030?

The hepatorenal syndrome market size has seen significant growth over recent years. It is anticipated to increase from $1.37 billion in 2025 to $1.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. This historical expansion can be attributed to the rising prevalence of chronic liver disease, an increase in cirrhosis-related complications, the development of intensive care unit infrastructure, heightened clinical awareness of HRS diagnosis, and the availability of vasoconstrictor-based therapies.

The hepatorenal syndrome market is projected to experience robust expansion over the coming years. It is anticipated to reach a valuation of $1.91 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth during the forecast period can be attributed to several factors, including an increase in liver transplant procedures, a heightened emphasis on early-stage HRS detection, the expansion of advanced renal support therapies, the growing adoption of precision medicine approaches, and increased investment in hepatology-focused clinical research. Key trends expected in the forecast timeframe include the increasing uptake of targeted vasoconstrictor therapies, a growing reliance on early diagnostic biomarkers, a stronger focus on multidisciplinary critical care management, the proliferation of albumin-based combination treatments, and enhanced monitoring of renal function in liver disease patients.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Hepatorenal Syndrome Market?

The increasing incidence of liver diseases is anticipated to spur the expansion of the hepatorenal syndrome market in the coming years. Liver diseases encompass various medical conditions that compromise the liver’s ability to function, such as hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases. The rise in liver diseases can be attributed to factors like obesity, diabetes, alcohol consumption, viral infections, inadequate nutrition, and exposure to toxins. This growing prevalence of liver ailments, including cirrhosis and acute liver failure, heightens the danger of hepatorenal syndrome (HRS) by leading to severe hemodynamic and renal dysfunction as liver impairment advances. For example, data from April 2024, provided by the Office for Health Improvement & Disparities (OHID), a UK government entity, indicated that UK hospital admissions for liver disease reached 155.2 per 100,000 in 2023, an increase from 150.6 per 100,000 in 2022. Consequently, the escalating prevalence of liver diseases is a key factor propelling the hepatorenal syndrome market forward.

What Are The Key Segment Divisions In The Hepatorenal Syndrome Market Segment Structure?

The hepatorenal syndrome market covered in this report is segmented –

1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome, Other Types

2) By Treatment: Liver Transplantation, Terlipressin Infusion, Albumin Infusion, Hemodialysis, Vasoconstrictors

3) By Diagnosis: Liver Function Tests, Urinalysis And Urine Electrolytes, Other Diagnoses

4) By End Users: Hospitals, Specialty Clinics

Subsegments:

1) By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS, Rapidly Progressive Renal Failure

2) By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS, Slowly Progressive Renal Failure

3) By Other Types: HRS With Cirrhosis, HRS With Acute Liver Failure, HRS With Alcoholic Hepatitis

Which Trends Are Shaping The Hepatorenal Syndrome Market?

Companies within the hepatorenal syndrome market are concentrating on developing innovative technologies, such as cytopheretic devices, to enhance patient outcomes through the reduction of inflammation, stabilization of kidney function, and improved treatment efficacy for Hepatorenal Syndrome (HRS). The cytopheretic device (Cytosorb) is an extracorporeal blood purification treatment designed to decrease systemic inflammation and immune activation in critically ill individuals, including those with Hepatorenal Syndrome (HRS). For instance, in October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, secured FDA approval for its Selective Cytopheretic Device (SCD) for the management of hepatorenal syndrome (HRS). This advanced, cell-directed intervention targets hyperinflammation, a primary factor contributing to kidney dysfunction in patients experiencing acute-on-chronic liver failure. By employing immunomodulation, SCD helps regulate atypical immune responses, potentially aiding kidney recovery and improving patients’ eligibility for crucial liver transplants. Its effectiveness in enhancing solid organ function has been demonstrated in preclinical and clinical studies across various conditions such as sepsis, acute kidney injury (AKI), and cardiorenal syndrome.

Which Organizations Are Engaged In The Hepatorenal Syndrome Market?

Major companies operating in the hepatorenal syndrome market are Eli Lilly and Company, Baxter International Inc., Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals Ltd, La Jolla Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Cumberland Pharmaceuticals Inc., Innoviva Specialty Therapeutics Inc, BioVie Inc., SeaStar Medical, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc., AbbVie Inc., Bristol Myers Squibb, Novartis AG, Sanofi, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Bayer AG, AstraZeneca

Get The Full Hepatorenal Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report

Where Is The Hepatorenal Syndrome Market Primarily Concentrated By Region?

North America was the largest region in the hepatorenal syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatorenal syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Hepatorenal Syndrome Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report

Browse Through More Reports Similar to the Global Hepatorenal Syndrome Market 2026, By The Business Research Company

Heparin Market Report 2026

https://www.thebusinessresearchcompany.com/report/heparin-global-market-report

Hepatic Encephalopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Dumping Syndrome Market Report 2026

https://www.thebusinessresearchcompany.com/report/dumping-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795